Lantheus Holdings, Inc. (LNTH) Stock Analysis

Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs

Tue, September 22, 2026 at 12:00 PM UTC 2 min read

Lantheus has received final FDA approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), marking it as the only radiopharmaceutical deemed bioequivalent and therapeutically equivalent to LUTATHERA® for treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This approval is significant for investors as it expands Lantheus's product portfolio in a niche market, potentially driving revenue growth and enhancing the company's competitive position in the oncology sector.

Read full article →

Curium acquisition of Lantheus backed by $5.375B of debt financing

Wed, August 26, 2026 at 8:56 PM UTC 3 min read

Lantheus Holdings (LNTH) is set to be acquired by Curium in a deal supported by $5.375 billion in debt financing. This acquisition is significant for investors as it highlights Curium's commitment to expanding its portfolio in the radiopharmaceutical sector, potentially enhancing Lantheus's market position and growth prospects. Investors should monitor how this acquisition impacts Lantheus's operational strategy and financial performance moving forward.

Read full article →